Concern access and adoption barriers could limit huge savings from Humira biosimilars in US market
The US biosimilars industry is approaching a watershed moment, says a not-for-profit organization charged with advancing such drugs.
Archives for July 20, 2022
EMA accepts application for Polpharma Biologics’ MS biosimilar natalizumab
Polpharma Biologics’ Marketing Authorization Application for natalizumab – a proposed biosimilar to Biogen’s Tysabri – has been accepted by the European Medicines Agency (EMA).
How can biosimilar companies attract the right talent?
Recruiting and nurturing talent will be incredibly important in the biosimilar industry as it continues its rapid evolution, according to RSA Talent Equity.